Preparation, biodistribution, and small animal PET of 45Ti- transferrin

Journal of Nuclear Medicine

Volumn 46, Issue 4, 2005, Pages 683-690

  Vavere, Amy L ^a,b   Welch, Michael J ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c MO   (United States)

Author keywords

45Ti; MicroPET; Transferrin

Indexed keywords

GALLIUM CITRATE GA 67; TITANIUM; TRANSFERRIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; FEMALE; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MOUSE STRAIN; NONHUMAN; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; ANIMAL; ANIMAL DISEASE; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; DRUG SCREENING; EXPERIMENTAL NEOPLASM; METABOLISM; METHODOLOGY; MOUSE; SCINTISCANNING; SPRAGUE DAWLEY RAT; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; FEMALE; ISOTOPE LABELING; MALE; MAMMARY NEOPLASMS, ANIMAL; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; ORGAN SPECIFICITY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 19644364626     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kopf-Maier P, Kopf H. Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes: early transition metal antitumor drugs. In: Fricker SP, ed. Metal Compounds in Cancer Therapy. London, U.K.: Chapman and Hall; 1994:109-146.
2. Christodoulou CV, Ferry DR, Fyfe DW, et al. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer. J Clin Oncol. 1998;16:2761-2769.
3. Harding MM, Mokdsi G. Antitumor metallocenes: structure-activity studies and interactions with biomolecules. Curr Med Chem. 2000;7:1289-1303.
4. Koepf-Maier P, Koepf H. Non-platinum group metal antitumor agents: history, current status, and perspectives. Chem Rev. 1987;87:1137-1152.
5. Koepf-Maier P, Koepf H. Transition and main-group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type. Struct Bond (Berlin). 1988;70:103-194.
6. Koepf-Maier P, Krahl D. Intracellular distribution of titanium after treatment with the antitumor agent titanocene dichloride: an electron energy loss spectroscopic study. Naturwissenschaften. 1981;68:273-274.
7. Koepf-Maier P, Wagner W, Liss E. Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metaliocene dichlorides and cis-platinum in vitro. J Cancer Res Clin Oncol. 1983;106:44-52.
8. 2, M = titanium, vanadium, or zirconium: aqueous kinetics, equilibria, and mechanistic implications for a new class of antitumor agents. J Am Chem Soc. 1985;107:947-953.
9. Guo M, Sun H, McArdle HJ, Gambling L, Sadler PJ. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry. 2000;39:10023-10033.
10. Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet. 1980;316:390-392.
11. Panaccio M, Zalcberg JR, Thompson CH, et al. Heterogeneity of the human transferrin receptor and use of anti-transferrin receptor antibodies to detect tumours in vivo. Immunol Cell Biol. 1987;65:461-472.
12. Li H, Sadler PJ, Sun H. Rationalization of the strength of metal binding to human serum transferrin. Eur J Biochem. 1996;242:387-393.
13. IV-protein complex: potential relevance to anticancer activity of titanocenes. Angew Chem Int Edn Engl. 1998;37:1577-1579.
14. Messori L, Orioli P, Banholzer V, Pais I, Zatta P. Formation of titanium(IV) transferrin by reaction of human serum apotransferrin with titanium complexes. FEBS Lett. 1999;442:157-161.
15. Kratz F, Hartmann M, Keppler B, Messori L. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem. 1994;269: 2581-2588.
16. Kratz F, Beyer U. Serum proteins as drug carriers of anticancer agents: a review. Drug Deliv. 1998;5:281-299.
17. Tsan MF, Scheffel U. Mechanism of gallium-67 accumulation in tumors. J Nucl Med. 1986;27:1215-1219.
18. Larson SM, Rasey JS, Allen DR, et al. Common pathway for tumor cell uptake of gallium-67 and iron-59 via a transferrin receptor. J Natl Cancer Inst. 1980; 64:41-53.
19. Larson SM, Rasey JS, Allen DR. The transferrin-receptor hypothesis: mechanism of tumor uptake of carrier-free gallium-67. In: Horst W, Wagner HN Jr, Buchanan J, eds. Frontiers in Nuclear Medicine. Berlin, Germany: Springer-Verlag; 1980:134-153.
20. Rasey JS, Larson SM, Huebers H. Transferrin-mediated uptake of iron and gallium in three nonhematopoietic tumor cell lines. In: Saltman P, Hegenuer, J, eds. The Biochemistry and Physiology of Iron: Proceedings of the 5th International Conference on Problems of Iron Storage and Transport, University of California, San Diego, Aug 24-26, 1981. New York, NY: Elsevier; 1982:225-227.
21. Larson SM, Rasey JS, Allen DR, Grunbaum Z. A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. II. Studies in vivo (BALB/c mice): concise communication. J Nucl Med. 1979;20:843-846.
22. Larson SM, Rasey JS, Allen DR, Nelson NJ. A transferrin-mediated uptake of gallium-67 by EMT-6 sarcoma. I. Studies in tissue culture. J Nucl Med. 1979; 20:837-842.
23. Coleman RE. Single photon emission computed tomography and positron emission tomography in cancer imaging. Cancer. 1991;67:1261-1270.
24. Schuster DM, Alazraki N. Gallium and other agents in diseases of the lung. Semin Nucl Med. 2002;32:193-211.
25. Ishiwata K, Ido T, Monma M, et al. Potential radiopharmaceuticals labeled with titanium-45. Appl Radiat Isot. 1991;42:707-712.
26. 45Ti-labeled compounds and their medical application. J Labelled Compds Radiopharm. 1982;19:11-12.
27. Vavere AL, Jones LR, McCarthy TJ, Rowland DJ, Welch MJ. Preparation, biodistribution, and microPET imaging of titanium-45-transferrin. J Labelled Compds Radiopharm. 2001;44:793-795.
28. Luttropp CA, Jackson JA, Jones BJ, Sohn M-H, Lynch RE, Morton KA. Uptake of gallium-67 in transfected cells and tumors absent or enriched in the transferrin receptor. J Nucl Med. 1998;39:1405-1411.
29. Guo M, Sun H, Bihari S, et al. Stereoselective formation of seven-coordinate titanium(IV) monomer and dimer complexes of ethylenebis(o-hydroxyphenyl) glycine. Inorg Chem. 2000;39:206-215.